Metabolic Dysfunction-associated Steatohepatitis (MASH)

DBCOND0161012Digestive System DiseasesNutritional and Metabolic Diseases

Metabolic Dysfunction-associated Steatohepatitis (MASH) is the indication for 3 drugs in DrugBank. It is covered by 6 curated, structured indications.

Also known as
Nonalcoholic Steatohepatitis · Non-Alcoholic Fatty Liver Disease · Non-Alcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Fatty Liver Disease · Fatty Liver Disease, Nonalcoholic
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0533561ICD-10K75.81SNOMED CT1231824009MedDRA10029530UMLSC0400966

What you can answer from here — as of September 29, 2026

3Indicated drugsWith each drug's targets and mechanism
Listed above
6Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
831Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Metabolic Dysfunction-associated Steatohepatitis (MASH) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In